Actively Recruiting
BPC 157 for Acute Hamstring Muscle Strain Repair
Led by Hudson Biotech · Updated on 2026-02-27
120
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
CONDITIONS
Official Title
BPC 157 for Acute Hamstring Muscle Strain Repair
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 45 years
- Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening
- MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus with measurable lesion
- Pre-injury physical activity of 3 or more sessions per week or participation in organized recreational sport
- Willingness to follow the standardized rehabilitation protocol and attend all study visits
- For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose
You will not qualify if you...
- Grade III hamstring tear, tendon avulsion, or injury requiring surgical management
- Concomitant lower extremity injury interfering with rehabilitation or outcome assessment
- Prior hamstring strain on the index limb within the past 6 months
- Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening
- Known bleeding disorder or current therapeutic anticoagulation
- Significant uncontrolled medical illness such as severe cardiovascular, hepatic, or renal disease
- Known allergy or hypersensitivity to components of the investigational product or placebo
- Pregnant or breastfeeding
- Current participation in another interventional clinical study or participation within 30 days prior to screening
- Subject to formal anti-doping testing program where investigational peptide use could create a regulatory conflict unless approved by relevant authority
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China, 518036
Actively Recruiting
Research Team
S
Seni S Lu, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here